The invention relates to a pharmaceutical composition comprising (i) a live strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp, (ii) an attenuated strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp or, (iii) a medically active substance isolated from a strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp.

The invention relates to a pharmaceutical composition comprising (i) a live strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp, (ii) an attenuated strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp or, (iii) a medically active substance isolated from a strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp.

The present invention relates to a composition comprising antigenic material of keratinophilic fungi and/or keratinophilic yeasts for use in a method of treating and/or preventing hoof- and claw diseases in animals and a new Trichophyton verrucosum strain which can e.g. be used in such a method of treatment and/or prevention.

The present invention relates to a composition comprising antigenic material of keratinophilic fungi and/or keratinophilic yeasts for use in a method of treating and/or preventing hoof- and claw diseases in animals and a new Trichophyton verrucosum strain which can e.g. be used in such a method of treatment and/or prevention.

Enfumafungin derivative triterpenoid antifungal compounds are used to treat or prevent fungal infections occurring in or under acidic conditions where the pH is lower than about 7, due to their unexpected, enhanced efficacy under such conditions. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment or prevention of yeast or mold infections that occur in anatomic areas having a low pH, such as the vaginal cavity, or under acidic local environment conditions such of those seen in fungal abscesses, empyema, or upper gastrointestinal tract infections.

Enfumafungin derivative triterpenoid antifungal compounds are used to treat or prevent fungal infections occurring in or under acidic conditions where the pH is lower than about 7, due to their unexpected, enhanced efficacy under such conditions. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment or prevention of yeast or mold infections that occur in anatomic areas having a low pH, such as the vaginal cavity, or under acidic local environment conditions such of those seen in fungal abscesses, empyema, or upper gastrointestinal tract infections.

The present invention relates to nucleic acids of the general formula (I): (N.sub.uG.sub.lX.sub.mG.sub.nN.sub.v).sub.a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (N.sub.uG.sub.lX.sub.mG.sub.nN.sub.v).sub.a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

The present invention provides compounds, compositions thereof, and methods of using the same.

The invention generally provides methods of treating or preventing aspergillosis disease and/or its symptoms associated with infection by the Aspergillus pathogenic fungus. The methods involve administering an Aspergillus Kexin peptide, or a composition comprising an Aspergillus peptide, to a mammalian subject in need thereof, such as a subject afflicted with aspergillus, or a subject susceptible to or at risk of infection by Aspergillus and ensuing aspergillosis disease. In some aspects, the Aspergillus Kexin peptide is an A. fumigatus Kexin peptide. In some aspects, the mammalian subject is a human patient. In some aspects, the patient is immunosuppressed or immunocompromised. The Aspergillus Kexin peptide as immunogen or vaccine generates a potent and robust immune response, e.g., antibody response, in the immunized subject. The methods afford therapeutic and protective treatment against aspergillosis and its symptoms, as well as a reduction in the severity of aspergillosis in the treated subjects.

The invention generally provides methods of treating or preventing aspergillosis disease and/or its symptoms associated with infection by the Aspergillus pathogenic fungus. The methods involve administering an Aspergillus Kexin peptide, or a composition comprising an Aspergillus peptide, to a mammalian subject in need thereof, such as a subject afflicted with aspergillus, or a subject susceptible to or at risk of infection by Aspergillus and ensuing aspergillosis disease. In some aspects, the Aspergillus Kexin peptide is an A. fumigatus Kexin peptide. In some aspects, the mammalian subject is a human patient. In some aspects, the patient is immunosuppressed or immunocompromised. The Aspergillus Kexin peptide as immunogen or vaccine generates a potent and robust immune response, e.g., antibody response, in the immunized subject. The methods afford therapeutic and protective treatment against aspergillosis and its symptoms, as well as a reduction in the severity of aspergillosis in the treated subjects.